Análisis económico regional del comercio fronterizo colombo-ecuatoriano en función de los indicadores macroeconómicos nacionales

Este documento hace un comparativo entre las condiciones económicas regionales que ha tenido el departamento de Nariño frente al comportamiento de los indicadores macroeconómicos que registran estadísticamente las instituciones nacionales (DANE, DIAN) del suroccidente colombiano. El comercio binacional de productos de consumo por la frontera sur, ha generado variaciones en el Índice de Precios al Consumidor (IPC), la inflación,la tasa de desempleo, la revaluación y devaluación del peso colombiano frente al dólar. Las tasas de cambio paralelas que se transan en la frontera sur, nos obliga a estudiar y comprender las causas y los efectos que se suscitan a partir de los flujos diarios de mercancías que se comercializan legal e ilegalmente, cuyos volúmenes de compra y venta incide relativamente en el bienestar de las comunidades colindantes. Conocer el comportamiento histórico de la macroeconomía colombiana y su incidencia en las actividades comerciales regionales de Nariño, como único territorio en donde confluyen dos (2) mercados (compra y venta de productos colombianos y ecuatorianos que forman parte de la canasta familiar regional), que operan simultáneamente en los diez (10) municipios zonas de frontera (Ley 191 de 1995). Estos indicadores han sido estudiados utilizando el método analíticodescriptivo en la modelización y contrastación de datos sobre las comparaciones cualitativas y comparativas de las series de tiempos, aplicadas a las actividades comerciales que tienen permanente influencia cambiaria, aduanera, geopolítica, logística y meso económica, desde su contexto de comercio-ambiente-frontera-región, predominantes. Lo anterior, desde la perspectiva regional intrafronteriza, en donde el incremento del comercio binacional, deja su efecto en las comunidades colindantes por los cordones fronterizos andino (Ipiales–Tulcán), pacífico (Tumaco-Esmeraldas) y amazónico (San Miguel–Lago Agrio)

Economía naranja y la actividad artesanal en Colombia y Nariño: una breve revisión analítica

La economía naranja ha sido objeto de especial atención recientemente, pues pone de manifiesto áreas que conservan un alto nivel de creatividad e innovación en sus productos finales, ya sea de orden digital o manual, con el propósito de abrir espacios de invención para la creación de nuevas plazas laborales, así como de información, conocimiento y aplicaciones varias. Por esta razón, en el presente artículo se hace una revisión teórica y estadística, que vislumbra la situación actual de esta rama en Colombia y Nariño, teniendo como eje principal la actividad artesanal. Entre los principales resultados, se encontraron evidentes dificultades para el conjunto de productores artesanales, en particular, frente a su nivel de ingresos, grado educativo y situación de pobreza

Impacto económico del TLC Estados Unidos-Colombia en el departamento de Nariño -primera parte-

En este trabajo se realiza un análisis del Tratado de Libre Comercio TLC, Estados Unidos-Colombia entrado en vigor en mayo de 2012 frente a la estructura económica del Departamento de Nariño. El Grupo de Investigación Frontera Sur, realiza un ejercicio exploratorio y analítico-descriptivo donde se aborda las luces y sombras del tratado para la economía regional. En efecto, se estudia las bondades y consecuencias del comercio internacional desde las distintas escuelas del pensamiento económico y sus aportes más relevantes a la teoría del comercio. En adelante, se analiza los términos del tratado, y su impacto en la economía regional, lo que permite resaltar las características de la estructura productiva de Nariño en un contexto de economía de frontera. Este documento se ha dividido en dos partes por su importancia y por la inuencia que puede llegar a tener en el mediano y largo plazo en el desarrollo regional de Nariño

Tarteso. Nuevas Fronteras (I)

El presente volumen recoge las contribuciones presentadas al II Congreso Internacional sobre Tarteso, Nuevas Fronteras, que tuvo lugar en Mérida entre los días 17 y 19 de noviembre de 2021. Su lectura permite un viaje desde el extremo oriental del Mediterráneo hasta el suroeste de la península ibérica, mostrando las diversas realidades históricas acontecidas en este territorio durante la I Edad del Hierro. El objetivo de esta publicación es mostrar la situación que atravesaba el Mediterráneo durante los años de surgimiento y desarrollo de la cultura tartésica para así comprender mejor la formación y evolución de dicha cultura. El conocimiento de Tarteso ha evolucionado sensiblemente en la última década, desde la celebración y publicación de las actas del I Congreso Internacional, Tarteso. El emporio del metal (Almuzara, 2013). La incorporación de nuevas voces y visiones enfocadas al conocimiento de la protohistoria peninsular, así como de algunos temas nunca antes abordados en el conocimiento de Tarteso, permiten presentar en este volumen una visión renovada, donde destaca la incorporación de unos nuevos límites territoriales para esta cultura.Esta publicación se ha beneficiado de las siguientes ayudas para su financiación: Proyecto de Investigación del Plan Nacional I+D+i: “Construyendo Tarteso 2.0: análisis constructivo, espacial y territorial de un modelo arquitectónico en el valle medio del Guadiana” (PID2019-108180GB- I00), financiado por MCIN AEI/10.13039/501100011033). Subvención global de la Secretaría General de Ciencia, Tecnología, Innovación y Universidad de la Junta de Extremadura al Instituto de Arqueología.Peer reviewe

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn’s disease (CD) patients in real-world clinical practice. Methods A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety. Results A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologic therapy, 141 (30.5%) of whom had received ≥3 agents. In addition, 35.2% received concomitant immunosuppressants, and 47.1% had ≥1 abdominal surgery. At week 16, 56% had remission, 70% had response, and 26.1% required dose escalation or intensification; of these, 24.8% did not subsequently reduce dose. After a median follow-up of 15 months, 356 (77%) patients continued treatment. The incidence rate of ustekinumab discontinuation was 18% per patient-year of follow-up. Previous intestinal surgery and concomitant steroid treatment were associated with higher risk of ustekinumab discontinuation, while a maintenance schedule every 12 weeks had a lower risk; neither concomitant immunosuppressants nor the number of previous biologics were associated with ustekinumab discontinuation risk. Fifty adverse events were reported in 39 (8.4%) patients; 4 of them were severe (2 infections, 1 malignancy, and 1 fever). Conclusions Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

Ustekinumab has shown efficacy in Crohn's Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. The objective of this analysis was to determine whether baseline patient characteristics are predictive of remission and the drug durability of ustekinumab, and whether its positioning with respect to prior use of biologics has a significant effect after correcting for disease severity and phenotype at baseline using interpretable machine learning. Patients' data from SUSTAIN, a retrospective multicenter single-arm cohort study, were used. Disease phenotype, baseline laboratory data, and prior treatment characteristics were documented. Clinical remission was defined as the Harvey Bradshaw Index <= 4 and was tracked longitudinally. Drug durability was defined as the time until a patient discontinued treatment. A total of 439 participants from 60 centers were included and a total of 20 baseline covariates considered. Less exposure to previous biologics had a positive effect on remission, even after controlling for baseline disease severity using a non-linear, additive, multivariable model. Additionally, age, body mass index, and fecal calprotectin at baseline were found to be statistically significant as independent negative risk factors for both remission and drug survival, with further risk factors identified for remission

Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case-control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March-July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3-5.9), occupational risk (OR: 2.9; 95%CI: 1.8-4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2-2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09-0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution

Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study

Background The clinical heterogeneity of COVID-19 suggests the existence of different phenotypes with prognostic implications. We aimed to analyze comorbidity patterns in critically ill COVID-19 patients and assess their impact on in-hospital outcomes, response to treatment and sequelae. Methods Multicenter prospective/retrospective observational study in intensive care units of 55 Spanish hospitals. 5866 PCR-confirmed COVID-19 patients had comorbidities recorded at hospital admission; clinical and biological parameters, in-hospital procedures and complications throughout the stay; and, clinical complications, persistent symptoms and sequelae at 3 and 6 months. Findings Latent class analysis identified 3 phenotypes using training and test subcohorts: low-morbidity (n=3385; 58%), younger and with few comorbidities; high-morbidity (n=2074; 35%), with high comorbid burden; and renal-morbidity (n=407; 7%), with chronic kidney disease (CKD), high comorbidity burden and the worst oxygenation profile. Renal-morbidity and high-morbidity had more in-hospital complications and higher mortality risk than low-morbidity (adjusted HR (95% CI): 1.57 (1.34-1.84) and 1.16 (1.05-1.28), respectively). Corticosteroids, but not tocilizumab, were associated with lower mortality risk (HR (95% CI) 0.76 (0.63-0.93)), especially in renal-morbidity and high-morbidity. Renal-morbidity and high-morbidity showed the worst lung function throughout the follow-up, with renal-morbidity having the highest risk of infectious complications (6%), emergency visits (29%) or hospital readmissions (14%) at 6 months (p<0.01). Interpretation Comorbidity-based phenotypes were identified and associated with different expression of in-hospital complications, mortality, treatment response, and sequelae, with CKD playing a major role. This could help clinicians in day-to-day decision making including the management of post-discharge COVID-19 sequelae. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd

Role of age and comorbidities in mortality of patients with infective endocarditis

[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. [Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. [Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. [Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group